553 related articles for article (PubMed ID: 9895372)
1. Expression of Fas ligand by human gastric adenocarcinomas: a potential mechanism of immune escape in stomach cancer.
Bennett MW; O'connell J; O'sullivan GC; Roche D; Brady C; Kelly J; Collins JK; Shanahan F
Gut; 1999 Feb; 44(2):156-62. PubMed ID: 9895372
[TBL] [Abstract][Full Text] [Related]
2. Fas (Apo-1/CD95) and Fas ligand interaction between gastric cancer cells and immune cells.
Lee TB; Min YD; Lim SC; Kim KJ; Jeon HJ; Choi SM; Choi CH
J Gastroenterol Hepatol; 2002 Jan; 17(1):32-8. PubMed ID: 11895550
[TBL] [Abstract][Full Text] [Related]
3. Fas ligand expression in primary colon adenocarcinomas: evidence that the Fas counterattack is a prevalent mechanism of immune evasion in human colon cancer.
O'Connell J; Bennett MW; O'Sullivan GC; Roche D; Kelly J; Collins JK; Shanahan F
J Pathol; 1998 Nov; 186(3):240-6. PubMed ID: 10211111
[TBL] [Abstract][Full Text] [Related]
4. Fas-related apoptosis in gastric adenocarcinoma.
Lim SC
Oncol Rep; 2003; 10(1):57-63. PubMed ID: 12469145
[TBL] [Abstract][Full Text] [Related]
5. The Fas counterattack in vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma.
Bennett MW; O'Connell J; O'Sullivan GC; Brady C; Roche D; Collins JK; Shanahan F
J Immunol; 1998 Jun; 160(11):5669-75. PubMed ID: 9605174
[TBL] [Abstract][Full Text] [Related]
6. Expression of Fas and Fas ligand in human gastric adenomas and intestinal-type carcinomas: correlation with proliferation and apoptosis.
Osaki M; Kase S; Kodani I; Watanabe M; Adachi H; Ito H
Gastric Cancer; 2001; 4(4):198-205. PubMed ID: 11846063
[TBL] [Abstract][Full Text] [Related]
7. Fas receptor counterattack against tumor-infiltrating lymphocytes in vivo as a mechanism of immune escape in gastric carcinoma.
Koyama S; Koike N; Adachi S
J Cancer Res Clin Oncol; 2001 Jan; 127(1):20-6. PubMed ID: 11206267
[TBL] [Abstract][Full Text] [Related]
8. Expression of Fas ligand in gastric carcinoma relates to lymph node metastasis.
Nagashima H; Mori M; Sadanaga N; Mashino K; Yoshikawa Y; Sugimachi K
Int J Oncol; 2001 Jun; 18(6):1157-62. PubMed ID: 11351245
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of Fas and Fas ligand system-associated apoptosis in gastric cancer.
Ohno S; Tachibana M; Shibakita M; Dhar DK; Yoshimura H; Kinugasa S; Kubota H; Masunaga R; Nagasue N
Ann Surg Oncol; 2000 Dec; 7(10):750-7. PubMed ID: 11129423
[TBL] [Abstract][Full Text] [Related]
10. Mechanism of counterattack of colorectal cancer cell by Fas/Fas ligand system.
Zhu Q; Liu JY; Xu HW; Yang CM; Zhang AZ; Cui Y; Wang HB
World J Gastroenterol; 2005 Oct; 11(39):6125-9. PubMed ID: 16273638
[TBL] [Abstract][Full Text] [Related]
11. Correlation of Fas/FasL expression to cell apoptosis in Epstein-Barr virus-associated gastric carcinoma.
He D; Xiao L; Chen JN; Liang Q; Shao CK
Chin J Cancer; 2010 Mar; 29(3):283-7. PubMed ID: 20193111
[TBL] [Abstract][Full Text] [Related]
12. Expression of FAP-1 by human colon adenocarcinoma: implication for resistance against Fas-mediated apoptosis in cancer.
Yao H; Song E; Chen J; Hamar P
Br J Cancer; 2004 Nov; 91(9):1718-25. PubMed ID: 15494722
[TBL] [Abstract][Full Text] [Related]
13. Expression of Fas ligand and caspase-3 contributes to formation of immune escape in gastric cancer.
Zheng HC; Sun JM; Wei ZL; Yang XF; Zhang YC; Xin Y
World J Gastroenterol; 2003 Jul; 9(7):1415-20. PubMed ID: 12854132
[TBL] [Abstract][Full Text] [Related]
14. Fas ligand upregulation is an early event in colonic carcinogenesis.
Bennett MW; O'Connell J; Houston A; Kelly J; O'Sullivan GC; Collins JK; Shanahan F
J Clin Pathol; 2001 Aug; 54(8):598-604. PubMed ID: 11477113
[TBL] [Abstract][Full Text] [Related]
15. Expression of Fas (CD95/APO-1) ligand by human breast cancers: significance for tumor immune privilege.
O'Connell J; Bennett MW; O'Sullivan GC; O'Callaghan J; Collins JK; Shanahan F
Clin Diagn Lab Immunol; 1999 Jul; 6(4):457-63. PubMed ID: 10391843
[TBL] [Abstract][Full Text] [Related]
16. Fas ligand and tumour counter-attack in colorectal cancer stratified according to microsatellite instability status.
Michael-Robinson JM; Pandeya N; Cummings MC; Walsh MD; Young JP; Leggett BA; Purdie DM; Jass JR; Radford-Smith GL
J Pathol; 2003 Sep; 201(1):46-54. PubMed ID: 12950016
[TBL] [Abstract][Full Text] [Related]
17. Fas ligand and Fas receptor are coexpressed in normal human esophageal epithelium: a potential mechanism of apoptotic epithelial turnover.
Bennett MW; O'Connell J; O'Sullivan GC; Roche D; Brady C; Collins JK; Shanahan F
Dis Esophagus; 1999; 12(2):90-8. PubMed ID: 10466040
[TBL] [Abstract][Full Text] [Related]
18. Fas ligand mediates immune privilege and not inflammation in human colon cancer, irrespective of TGF-beta expression.
Houston A; Bennett MW; O'Sullivan GC; Shanahan F; O'Connell J
Br J Cancer; 2003 Oct; 89(7):1345-51. PubMed ID: 14520470
[TBL] [Abstract][Full Text] [Related]
19. [Expression and function of apoptosis-related genes Bcl-2/Bax and Fas/Fas L in the course of stress ulcer].
Liu J; Li ZS; Wan XJ; Wang W
Zhonghua Yi Xue Za Zhi; 2003 Mar; 83(6):504-9. PubMed ID: 12887767
[TBL] [Abstract][Full Text] [Related]
20. Fas ligand expressed in colon cancer is not associated with increased apoptosis of tumor cells in vivo.
Houston A; Waldron-Lynch FD; Bennett MW; Roche D; O'Sullivan GC; Shanahan F; O'Connell J
Int J Cancer; 2003 Nov; 107(2):209-14. PubMed ID: 12949796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
